These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 8604347)

  • 1. Phosphorylation of p53 at the casein kinase II site selectively regulates p53-dependent transcriptional repression but not transactivation.
    Hall SR; Campbell LE; Meek DW
    Nucleic Acids Res; 1996 Mar; 24(6):1119-26. PubMed ID: 8604347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The carboxy-terminal serine 392 phosphorylation site of human p53 is not required for wild-type activities.
    Fiscella M; Zambrano N; Ullrich SJ; Unger T; Lin D; Cho B; Mercer WE; Anderson CW; Appella E
    Oncogene; 1994 Nov; 9(11):3249-57. PubMed ID: 7936649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repression of glucocorticoid receptor transactivation and DNA binding of a glucocorticoid response element within the serum/glucocorticoid-inducible protein kinase (sgk) gene promoter by the p53 tumor suppressor protein.
    Maiyar AC; Phu PT; Huang AJ; Firestone GL
    Mol Endocrinol; 1997 Mar; 11(3):312-29. PubMed ID: 9058378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2.
    Dumaz N; Meek DW
    EMBO J; 1999 Dec; 18(24):7002-10. PubMed ID: 10601022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation of the casein kinase II phosphorylation site abolishes the anti-proliferative activity of p53.
    Milne DM; Palmer RH; Meek DW
    Nucleic Acids Res; 1992 Nov; 20(21):5565-70. PubMed ID: 1454521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein kinase CK2-dependent regulation of p53 function: evidence that the phosphorylation status of the serine 386 (CK2) site of p53 is constitutive and stable.
    McKendrick L; Milne D; Meek D
    Mol Cell Biochem; 1999 Jan; 191(1-2):187-99. PubMed ID: 10094408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.
    Fischer M; Quaas M; Nickel A; Engeland K
    Oncotarget; 2015 Dec; 6(39):41402-17. PubMed ID: 26595675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of p53 mediated transactivation by the beta-subunit of protein kinase CK2.
    Schuster N; Prowald A; Schneider E; Scheidtmann KH; Montenarh M
    FEBS Lett; 1999 Mar; 447(2-3):160-6. PubMed ID: 10214938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein p53 modulates transcription from a promoter containing its binding site in a concentration-dependent manner.
    Kristjuhan A; Maimets T
    Eur J Biochem; 1995 Dec; 234(3):827-31. PubMed ID: 8575441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific DNA binding by p53 is independent of mutation at serine 389, the casein kinase II site.
    Rolley N; Milner J
    Oncogene; 1994 Oct; 9(10):3067-70. PubMed ID: 8084615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site.
    Blaydes JP; Hupp TR
    Oncogene; 1998 Aug; 17(8):1045-52. PubMed ID: 9747884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of mutant p53 phosphorylation at serine 15 or serine 315 partially restores the function of wild-type p53.
    Sugikawa E; Yazaki N; Tsunoda S; Nakanishi N; Ohashi M
    Biochem Biophys Res Commun; 1999 Aug; 261(2):256-63. PubMed ID: 10425175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-derived p53 mutant C174Y is a gain-of-function mutant which activates the fos promoter and enhances colony formation.
    Preuss U; Kreutzfeld R; Scheidtmann KH
    Int J Cancer; 2000 Oct; 88(2):162-71. PubMed ID: 11004663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of transcription factors c-Myc, Max, and c-Myb by casein kinase II.
    Bousset K; Oelgeschläger MH; Henriksson M; Schreek S; Burkhardt H; Litchfield DW; Lüscher-Firzlaff JM; Lüscher B
    Cell Mol Biol Res; 1994; 40(5-6):501-11. PubMed ID: 7735324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel system to investigate the phosphorylation of the p53 tumor suppressor protein by the protein kinase CK2.
    McKendrick L; Meek DW
    Cell Mol Biol Res; 1994; 40(5-6):555-61. PubMed ID: 7735330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the DNA-binding ability of latent p53 protein by protein kinase C is abolished by protein kinase CK2.
    Pospísilová S; Brázda V; Kucharíková K; Luciani MG; Hupp TR; Skládal P; Palecek E; Vojtesek B
    Biochem J; 2004 Mar; 378(Pt 3):939-47. PubMed ID: 14640983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serine-173 of the Epstein-Barr virus ZEBRA protein is required for DNA binding and is a target for casein kinase II phosphorylation.
    Kolman JL; Taylor N; Marshak DR; Miller G
    Proc Natl Acad Sci U S A; 1993 Nov; 90(21):10115-9. PubMed ID: 8234266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raf phosphorylates p53 in vitro and potentiates p53-dependent transcriptional transactivation in vivo.
    Jamal S; Ziff EB
    Oncogene; 1995 Jun; 10(11):2095-101. PubMed ID: 7784054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage.
    Di Stefano V; Soddu S; Sacchi A; D'Orazi G
    Oncogene; 2005 Aug; 24(35):5431-42. PubMed ID: 15897882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single serine residue at position 375 of VP16 is critical for complex assembly with Oct-1 and HCF and is a target of phosphorylation by casein kinase II.
    O'Reilly D; Hanscombe O; O'Hare P
    EMBO J; 1997 May; 16(9):2420-30. PubMed ID: 9171355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.